Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch & Kristina Ellwanger. (2023) Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method. mAbs 15:1.
Read now
Read now
Meixiao Long, Alice S. Mims & Zihai Li. (2022) Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations 51:8, pages 2176-2214.
Read now
Read now
Francesca Del Bufalo, Pietro Merli, Iside Alessi & Franco Locatelli. (2019) B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Review of Clinical Immunology 15:5, pages 497-509.
Read now
Read now
Mattia Algeri, Francesca Del Bufalo, Federica Galaverna & Franco Locatelli. (2018) Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Review of Hematology 11:12, pages 945-956.
Read now
Read now
Articles from other publishers (18)
Jeffrey Lantz, Natalie Pham, Caroline Jones, Daniel Reed, Firas El Chaer & Michael Keng. (2023) Blinatumomab in Practice. Current Hematologic Malignancy Reports.
Crossref
Crossref
Yutaka Shimazu, Toshio Kitawaki, Tadakazu Kondo & Akifumi Takaori-Kondo. (2023) Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy.
Crossref
Crossref
Can Liu, Jiawei Zhou, Stephan Kudlacek, Timothy Qi, Tyler Dunlap & Yanguang Cao. (2023) Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. eLife 12.
Crossref
Crossref
Jiwon Yang, Jing Jiao, Kyle M. Draheim, Guoxiang Yang, Hongyuan Yang, Li‐Chin Yao, Leonard D. Shultz, Dale L. Greiner, Deepa Rajagopal, Sandrine Vessillier, Curtis C. Maier, Sunish Mohanan, Danying Cai, Mingshan Cheng, Michael A. Brehm & James G. Keck. (2023) Simultaneous evaluation of treatment efficacy and toxicity for bispecific T‐cell engager therapeutics in a humanized mouse model. The FASEB Journal 37:6.
Crossref
Crossref
Rajendran Ramesh & Ramakrishnan Ravichandran. 2023. Protein-based Therapeutics. Protein-based Therapeutics
199
232
.
Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine & Shahrukh K. Hashmi. (2022)
The forgotten survivor: A comprehensive review on
Non‐Hodgkin
lymphoma survivorship
. American Journal of Hematology 97:12, pages 1627-1637.
Crossref
Crossref
Pauline Mocquot, Yasmine Mossazadeh, Léopoldine Lapierre, Fanny Pineau & Fabien Despas. (2022) The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. Journal of Clinical Pharmacy and Therapeutics 47:9, pages 1337-1351.
Crossref
Crossref
Katarzyna Pawinska-Wasikowska, Aleksandra Wieczorek, Walentyna Balwierz, Karolina Bukowska-Strakova, Marta Surman & Szymon Skoczen. (2022) Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers 14:2, pages 458.
Crossref
Crossref
Aina Segués, Shuyu Huang, Alice Sijts, Pedro Berraondo & Dietmar M. Zaiss. 2022. New Antibody Formats. New Antibody Formats
45
70
.
Zhaoming Wang, Chaobo Yin, Lawrence G. Lum, Andrean Simons & George J. Weiner. (2021) Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Yi Huo, Zhen Sheng, Daniel R. Lu, Daniel C. Ellwanger, Chi-Ming Li, Oliver Homann, Songli Wang, Hong Yin & Ruibao Ren. (2021) Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genomics 22:1.
Crossref
Crossref
Gordana Wozniak-Knopp. 2021. Introduction to Antibody Engineering. Introduction to Antibody Engineering
161
187
.
Veysel Kayser & Mehmet Sen. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
213
236
.
Shanmuganathan Chandrakasan & Manish J. Butte. 2020. Stiehm's Immune Deficiencies. Stiehm's Immune Deficiencies
1099
1111
.
Annie Im & Steven Z. Pavletic. (2017) Immunotherapy in hematologic malignancies: past, present, and future. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Steffi Lehmann, Ramanil Perera, Hans-Peter Grimm, Johannes Sam, Sara Colombetti, Tanja Fauti, Linda Fahrni, Teilo Schaller, Anne Freimoser-Grundschober, Jörg Zielonka, Szymon Stoma, Markus Rudin, Christian Klein, Pablo Umana, Christian Gerdes & Marina Bacac. (2016)
In Vivo
Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
. Clinical Cancer Research 22:17, pages 4417-4427.
Crossref
Crossref
Stephanie A. Folan, Amber Rexwinkle, Jane Autry & Jeffrey C. Bryan. (2016) Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 16, pages S2-S5.
Crossref
Crossref
Jingjing Wu, Jiaping Fu, Mingzhi Zhang & Delong Liu. (2015) Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Crossref